Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcadia Biosciences (RKDA) Gross Margin (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Gross Margin readings, the most recent being 21.31% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 1068.0% to 21.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 36.21%, a 507.0% decrease, with the full-year FY2025 number at 36.23%, down 504.0% from a year prior.
  • Gross Margin hit 21.31% in Q4 2025 for Arcadia Biosciences, down from 32.1% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 115.49% in Q4 2022 to a low of 7.39% in Q1 2022.
  • Median Gross Margin over the past 5 years was 34.92% (2023), compared with a mean of 38.35%.
  • Biggest five-year swings in Gross Margin: soared 53006bps in 2021 and later tumbled -8916bps in 2022.
  • Arcadia Biosciences' Gross Margin stood at 12.7% in 2021, then surged by 809bps to 115.49% in 2022, then tumbled by -33bps to 77.09% in 2023, then tumbled by -59bps to 31.99% in 2024, then crashed by -33bps to 21.31% in 2025.
  • The last three reported values for Gross Margin were 21.31% (Q4 2025), 32.1% (Q3 2025), and 43.37% (Q2 2025) per Business Quant data.